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Pdentification of a Cytochrome
450 2C9-Derived Endothelium-Derived
yperpolarizing Factor in Essential Hypertensive Patients
tefano Taddei, MD, Daniele Versari, MD, Alessandro Cipriano, MD, Lorenzo Ghiadoni, MD, PHD,
abio Galetta, MD, Ferdinando Franzoni, MD, Armando Magagna, MD, Agostino Virdis, MD,
ntonio Salvetti, MD
isa, Italy
OBJECTIVES We assessed the role of cytochrome P450 2C9 (CYP 2C9)-derived endothelium-derived
hyperpolarizing factor (EDHF) in the forearm microcirculation of essential hypertensive
patients (EH) by utilizing sulfaphenazole (SUL), a selective CYP 2C9 inhibitor.
BACKGROUND In EH patients, EDHF acts as a compensatory pathway when nitric oxide (NO) availability
is reduced. Cytochrome P450 2C9 is a possible source of EDHF.
METHODS In 36 healthy subjects (normotensive [NT]) and 32 hypertensive patients (HT), we studied
forearm blood flow (strain-gauge plethysmography) changes induced by intraarterial acetyl-
choline (ACH) and bradykinin (BDK), repeated during NG-monomethyl-L-arginine
(L-NMMA) (100 g/100 ml/min) or SUL (0.03 mg/100 ml/min). In HT, the effect of SUL
on ACH and BDK was repeated during vitamin C (8 mg/100 ml/min). Sodium nitroprusside
(SNP) was utilized as control.
RESULTS In NT, vasodilation to ACH and BDK was blunted by L-NMMA and not changed by SUL.
In contrast, in HT responses to ACH and BDK, reduced compared with NT, were resistant
to L-NMMA. In these patients, SUL blunted vasodilation to ACH and to a greater extent
the response to BDK. When retested with vitamin C, SUL was no longer effective on both
endothelial agonists. In 2 final groups of normotensive control subjects, vasodilation to ACH
or BDK residual to cyclooxygenase and L-NMMA blockade was further inhibited by
simultaneous SUL infusion. Response to SNP, similar between NT and HT, was unaffected
by SUL.
CONCLUSIONS Cytochrome P450 epoxygenase-derived EDHF acts as a partial compensatory mechanism to
sustain endothelium-dependent vasodilation in HT, particularly the BDK-mediated re-
sponse, when NO activity is impaired because of oxidative stress. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.07448:508–15) © 2006 by the American College of Cardiology Foundation
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lssential hypertension is characterized by the presence of
ndothelial dysfunction, acting as a mechanism promoting
therosclerosis and cardiovascular events (1). One of the
rincipal characteristics of endothelial dysfunction in
ypertension is the presence of impaired response to
ndothelium-dependent agonists, above all acetylcholine
ACH) or bradykinin (BDK), as compared with that in
ealthy control subjects (2–6). This diminished relaxing
esponse to ACH or BDK is, moreover, resistant to
G-monomethyl-L-arginine (L-NMMA), indicating the
resence of compromised nitric oxide (NO) availability
aused by oxidative stress (5,6). In these circumstances,
ther mediators account for the vascular relaxing effects of
hese compounds. Available evidence supports the possibil-
ty that endothelial factor(s) causing smooth muscle cells
yperpolarization (EDHF) act as a compensatory pathway
esponsible for endothelium-dependent vasodilation in
resence of reduced NO availability (6).
One of the possible pathways for EDHF involves the
ctivation of cytochrome P450 epoxygenase (CYP 2C),
hich is mainly expressed in endothelial cells (7). The role
From the Department of Internal Medicine, University of Pisa, Pisa, Italy.e
Manuscript received September 14, 2005; revised manuscript received March 27,
006, accepted April 11, 2006.f this enzyme in producing hyperpolarization is dependent
n the generation of metabolites of arachidonic acid (EET),
hich either initiate the endothelial cell hyperpolarization
8,9) or are released from endothelial cells to stimulate K
n vascular smooth muscle cells (10). CYP2C-derived
DHF has been identified in porcine coronary arteries (11)
nd human mammary arteries in vitro (12). In addition,
elective blockade of CYP 2C can blunt NO- and
rostacyclin-independent vasodilation to BDK in the fore-
rm microcirculation in healthy humans (13). On the other
and, CYP 2C9 could be also involved in the generation of
xygen free radicals, thereby leading to NO breakdown
14). In line with this possibility, a CYP 2C9-dependent
eduction in NO availability has been demonstrated in the
orearm microcirculation of patients with coronary artery
isease (15). Because essential hypertension is characterized
y both NO-independent vasodilation, likely mediated by
DHFs production, and oxidative stress, the aim of the
resent study was to investigate the possible role of CYP
C9 in modulating endothelial responses in essential hyper-
ensive patients. To address this issue, we tested the effect of
ulfaphenazole, a selective CYP 2C9 inhibitor, on vasodi-
ation to ACH and BDK in the peripheral circulation of
ssential hypertensive patients.
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atients. Thirty-six healthy subjects and 32 matched essen-
ial hypertensive patients participated in the study (Table 1).
ubjects with smoking history (more than 5 cigarettes per day),
thanol consumption (more than 60 g—half liter of wine—
er day), hypercholesterolemia (total cholesterol 200 mg/
l), diabetes mellitus, cardiac and/or cerebrovascular ische-
ic vascular disease, impaired renal function, and other
ajor pathologies were excluded. In accordance with insti-
utional guidelines, all patients were aware of the investiga-
ional nature of the study and gave written consent to it.
Subjects were defined as normal according to the absence
f familial history of essential hypertension and blood
ressure (BP) values below 140/90 mm Hg (Table 1).
ssential hypertensive patients were recruited from among
ewly diagnosed cases when they reported the presence of
ositive family history of essential hypertension and if
upine arterial BP (after 10 min of rest), measured 3 times
t 1-week intervals, was consistently found to be 140/90
m Hg (Table 1). Secondary forms of hypertension were
xcluded by routine diagnostic procedures. Patients were
nrolled if never treated (n  10) or reporting a history of
iscontinued or ineffective pharmacologic antihypertensive
reatment (n  22).
able 1. Characteristics of Study Subjects
Parameters
Normotensive
Subjects
(n  36)
Essential
Hypertensive
Patients
(n  32)
ge (yrs) 48.5  7.2 49.1  7.7
ender (male/female) 27/9 24/8
moking (yes/no) No No
ody mass index (kg/m2) 24.6  3.1 25.1  2.9
ystolic blood pressure (mm Hg) 114.6  3.9 154.3  7.1*
iastolic blood pressure (mm Hg) 79.8  4.6 101.4  5.6*
eart rate (beats/min) 68.4  5.9 71.7  6.2
lasma glucose (mmol/l) 4.70  0.7 4.74  0.5
lasma total cholesterol (mmol/l) 4.66  0.6 4.66  0.5
lasma HDL cholesterol (mmol/l) 1.21  0.5 1.20  0.3
lasma LDL cholesterol (mmol/l) 2.70  0.5 2.73  0.7
ata are mean  SD. *Indicates a statistically significant (p  0.05; t test) difference
Abbreviations and Acronyms
ACH  acetylcholine
BDK  bradykinin
BP  blood pressure
COX  cyclooxygenase
CYP 2C  cytochrome P450 epoxygenase
EDHF  endothelium-derived hyperpolarizing factor
EET  epoxyeicosatrienoic acid
FBF  forearm blood flow
L-NMMA  NG-monomethyl-L-arginine
NO  nitric oxide
SNP  sodium nitroprussidep
etween the 2 groups.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.xperimental model. Vascular reactivity was assessed by
he perfused forearm technique. Briefly, the brachial artery
as cannulated for drug infusion at systemically ineffective
ates, and for intraarterial BP and heart rate monitoring.
orearm blood flow (FBF) was measured in both forearms
experimental and contralateral forearm) by strain-gauge
enous plethysmography (3). Circulation to the hand was
xcluded 1 min before FBF measurement by inflating a
ediatric cuff around the wrist at suprasystolic BP. Details
oncerning the method as performed in our laboratory,
ncluding sensitivity and reproducibility, have already been
ublished (3,5).
tudy design. ENDOTHELIUM-DEPENDENT AND
NDOTHELIUM-INDEPENDENT VASODILATION. In 20
ormotensive subjects and 20 essential hypertensive pa-
ients, endothelium-dependent forearm vasodilatation was
valuated by obtaining a dose-response curve to intraarterial
CH (cumulative increase in infusion rates: from 0.15 to 15
g/100 ml of forearm tissue/min, 5’ each dose) and BDK
from 5 to 50 ng/100 ml tissue/min, 5’ each dose). In 8 of
0 normotensive subjects and 8 of 20 essential hypertensive
atients, endothelium-independent vasodilatation to so-
ium nitroprusside (SNP) (from 1 to 4 g/100 ml tissue/
in, 5’ each dose), which acts directly on the smooth muscle
ells, was also assessed.
FFECTS OF L-NMMA AND SULFAPHENAZOLE ON VASODI-
ATION TO ACH AND BDK. To compare the relative contri-
ution of NO and CYP 2C9-derived EDHF in
ndothelium-dependent vasodilation, in 12 of the previous
eries of 20 normotensive subjects and 12 of 20 hypertensive
atients, the dose-response curves to ACH and BDK were
erformed during saline (0.2 ml/min), in the presence of
-NMMA (100 g/100 ml tissue/min) or sulfaphenazole
0.03 g/100 ml tissue/min). Infusions under L-NMMA
ere performed according to the NO-clamp technique,
hich requires SNP co-infusion (0.4 and 0.3 g/100 ml
issue/min for 5’ in normotensive subjects and hypertensive
atients, respectively) in order to neutralize the L-NMMA–
nduced vasoconstriction and restore baseline FBF. Details
oncerning the method as performed in our laboratory have
lready been published (16).
To exclude any possible role of CYP 2C9 in endothelium-
ndependent vasodilation, in those groups of normotensive
ubjects and hypertensive patients assigned to SNP infusion, a
ose-response curve to this compound was repeated in the
resence of intra-arterial sulfaphenazole (0.03 g/100 ml
issue/min).
FFECT OF SIMULTANEOUS L-NMMA AND SULFAPHENAZOLE
DMINISTRATION IN NORMOTENSIVE SUBJECTS. This series
as designed to assess whether EDHF component of
ndothelium-dependent vasodilation can be unmasked un-
er inhibition of NO availability. Acetylcholine and BDK
ere infused in 2 further groups of n  8 normotensive
ubjects (each group) during saline (0.2 ml/min), in the
resence of L-NMMA (100 g/100 ml tissue/min) or
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oth L-NMMA and sulfaphenazole. To avoid any possible
nfluence of cyclooxygenase (COX)-derived vasoactive pro-
tanoids, all subjects were given oral acetylsalicylic acid (1 g)
h before the study.
To address the possibility that exogenous NO from the
NP co-infusion utilized for the “NO clamp” could have
ffects on EDHF pathway, in an adjunctive group (n  6)
f healthy subjects we performed the identical experimental
esign by replacing SNP with papaverine (150 g/100 ml
issue/min), a phosphodiesterase activity inhibitor.
OLE OF OXIDATIVE STRESS IN DETERMINING THE RE-
PONSE TO SULFAPHENAZOLE IN ESSENTIAL HYPERTENSIVE
ATIENTS. These series were designed to assess whether
xygen-free radical production can modulate the sulfa-
henazole sensitive pathway. Thus, in an adjunctive group
f 6 essential hypertensive patients, the dose-response
urves to ACH were performed during saline (0.2 ml/min)
nd in the presence of sulfaphenazole (0.03 g/100 ml
orearm tissue/min). These infusions were then repeated
nder intraarterial administration of vitamin C (8 mg/100
l forearm tissue/min), an antioxidant (17). Finally, in a
urther group of 6 essential hypertensive patients, the same
bove-described protocol was repeated but replacing ACH
ith BDK.
In each series, the sequence of the agonists was random-
zed. Sulfaphenazole and L-NMMA were started 10 min
efore ACH or BDK and continued throughout. A 30-min
ashout was allowed between each dose-response curve,
hile a 60-min period was allowed when L-NMMA was
nfused. These periods of time were validated in adjunctive
tudies.
In order to confirm that in essential hypertension oxygen-
ree radical inactivation by vitamin C restores the NO
vailability, in a final group (n 6) of hypertensive patients,
he dose-response curves to ACH were performed during
aline (0.2 ml/min) and in the presence of L-NMMA.
hese infusions were then repeated under intraarterial
dministration of vitamin C.
ata analysis. Data were analyzed in terms of changes in
BF. Because arterial BP did not change significantly during
he FBF study, increments in FBF were taken as evidence of
ocal vasodilation. Results are expressed as mean SD, except
or the figures (results described as mean SEM). Differences
etween 2 means were compared by the Student t test for
aired or unpaired observations, as appropriate. Responses to
CH, BDK, and SNP were analyzed by analysis of variance
or repeated measures, and Scheffé’s test was applied for
ultiple comparison testing. Differences were considered to be
tatistically significant when p was 0.05.
RUGS. Acetylcholine (Farmigea S.p.A., Pisa, Italy), BDK,
Cl, L-NMMA, papaverine, sulfaphenazole (Clinalfa AG,
äufelfingen, Switzerland), vitamin C (Bracco, Milan,
taly), and SNP (Malesci, Milan, Italy) were obtained from
ommercially available sources and diluted freshly to the Lesired concentration by adding normal saline. Sodium
itroprusside was dissolved in glucosate solution and pro-
ected from light by aluminum foil.
ESULTS
ge, gender, smoking history, and metabolic profile were
imilar, and within a normal range, between the 2 study
roups, differing only in BP values (Table 1).
ffect of L-NMMA and sulfaphenazole on response to
CH, BDK, and SNP in hypertensive patients. The
BF increase induced by ACH and BDK was significantly
educed in hypertensive patients as compared with normo-
ensive subjects (Table 2). In contrast, vasodilation to SNP
as similar in both groups (Table 2, Fig. 1). In normoten-
ive subjects, as expected, responses to ACH and BDK were
ignificantly blunted by L-NMMA (Table 2, Fig. 1). In
hese subjects, sulfaphenazole administration, which did not
ignificantly change basal FBF (data not shown), was devoid
f effects on responses to ACH and BDK (Table 2, Fig. 1).
ulfaphenazole also did not change the response to SNP
Fig. 1).
In hypertensive patients, responses to ACH and BDK
ere resistant to L-NMMA (Table 2, Fig. 1). In contrast,
n these patients, sulfaphenazole, while not modifying basal
BF (data not shown), significantly reduced the vasodila-
ion induced by ACH and BDK (Table 2, Fig. 1).
It is worth noting that the degree of percent inhibition
xerted by sulfaphenazole was greater on the response to
DK (26.9%) as compared with the response to ACH
15.1%) (Fig. 2). Vascular response to SNP was not affected
y the CYP 2C9 inhibitor (Fig. 1).
able 2. Maximal Absolute (ml/100 ml tissue/min) FBF
odifications Above Baseline During ACH, SNP, L-NMMA,
nd BDK Infusion
Normotensive
Subjects
Hypertensive
Patients
aseline 3.2  0.2 3.3  0.3
CH 21.4  3.0 16.5  2.7*
aseline 3.3  0.4 3.3  0.3
DK 22.4  3.1 15.7  2.9*
aseline 3.4  0.5 3.4  0.5
NP 17.3  3.6 17.5  4.1
aseline 3.3  0.4 3.4  0.4
-NMMA 2.0  0.2 2.4  0.4
-NMMA  SNP 3.3  0.4 3.3  0.5
-NMMA  SNP  ACH 11.7  0.7 15.9  2.9
aseline 3.3  0.2 3.4  0.3
-NMMA 2.1  0.3 2.3  0.4
-NMMA  SNP 3.4  0.3 3.4  0.5
-NMMA  SNP  BDK 13.0  0.6 15.2  2.4
aseline 3.2  0.3 3.2  0.3
ulfa  ACH 21.0  2.6 13.8  2.0
aseline 3.2  0.4 3.2  0.4
ulfa  BDK 21.1  3.0 11.7  1.2
p  0.01 vs. normotensive subjects.
ACH  acetylcholine; BDK  bradykinin; FBF  forearm blood flow;
-NMMA  NG-monomethyl-L-arginine; SNP  sodium nitroprusside.
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dministration in normotensive subjects. As in the pre-
ious series of experiments, sulfaphenazole did not change
he response to ACH, whereas L-NMMA infusion signif-
cantly blunted the vasodilator effect of the agonist (Table 3,
ig. 3). When ACH was finally repeated in the presence of
igure 1. Forearm blood flow (FBF) percent increase above basal induce
L-NMMA), or sulfaphenazole in normotensive subjects (n  12) and e
ncrease above basal induced by sodium nitroprusside (SNP) with or witho
.01 (by analysis of variance for repeated measures and Scheffé’s test).imultaneous sulfaphenazole and L-NMMA, we observed Fn inhibition of vasodilation to ACH (Table 3, Fig. 3),
hich was far greater than that observed with L-NMMA
lone. Similar data were observed when ACH was replaced
y BDK. Indeed, the vasodilation to BDK was unaffected by
ulfaphenazole, blunted by L-NMMA, and further reduced
y concomitant sulfaphenazole and L-NMMA (Table 3,
acetylcholine and bradykinin during saline, NG-monomethyl-L-arginine
al hypertensive patients (n  12). The lower panels show FBF percent
faphenazole. Data shown as mean  SEM. *p  0.001; †p  0.05; ‡p d by
ssenti
ut sulig. 3).
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Hyperpolarization in Essential Hypertension August 1, 2006:508–15Results obtained with papaverine were identical to those
een with SNP. Indeed, sulfaphenazole did not change the
esponse to ACH, and L-NMMA blunted the response to
CH. When ACH was repeated with simultaneous sulfa-
henazole and L-NMMA, a further inhibition of response
o ACH was seen (data not shown).
ffect of vitamin C on sulfaphenazole-induced inhibi-
ion of vasodilation to ACH and BDK in hypertensive
atients. In this group of hypertensive patients, the vaso-
ilation to ACH was inhibited by sulfaphenazole and
ncreased by vitamin C (Fig. 4). Of importance, sulfa-
henazole, when retested under vitamin C, no longer
nhibited the response to ACH (Figs. 2 and 4). Similarly,
asodilation to BDK was blunted by sulfaphenazole and
otentiated by vitamin C (Fig. 4). When co-infused with
he antioxidant, sulfaphenazole was no longer effective
Figs. 2 and 4).
igure 2. Percent inhibition by sulfaphenazole on maximal response to
cetylcholine (Ach) or bradykinin (Bdk) in normotensive subjects and
ssential hypertensive patients in control condition (saline) and under
itamin C. Data shown as mean  SEM. *p  0.001 versus other groups;
p  0.05 versus Ach under saline in hypertensive patients (by analysis of
ariance and Scheffs test).
able 3. Maximal Absolute (ml/100 ml tissue/min) FBF
hanges During Simultaneous L-NMMA and Sulfaphenazole
Normotensive Subjects
aseline 3.3  0.3
-NMMA 2.0  0.3
-NMMA  SNP 3.3  0.2
-NMMA  SNP  ACH 11.4  0.9
aseline 3.4  0.4
ulfa  L-NMMA 2.1  0.3
ulfa  L-NMMA  SNP 3.3  0.3
ulfa  L-NMMA  SNP  ACH 9.7  0.6
aseline 3.4  0.3
-NMMA 2.1  0.2
-NMMA  SNP 3.3  0.3
-NMMA  SNP  BDK 13.1  1.6
aseline 3.4  0.3
ulfa  L-NMMA 2.0  0.1
ulfa  L-NMMA  SNP 3.3  0.3
ulfa  L-NMMA  SNP  BDK 9.9  0.7bbbreviations as in Table 2.In the final group of hypertensive patients, the vaso-
ilation to ACH (saline: from 3.3  0.2 ml/100 ml/min
o 16.2  2.8 ml/100 ml/min, 391%) was resistant
o L-NMMA (baseline: 3.3  0.4 ml/100 ml/min;
-NMMA: 2.1  0.4 ml/100 ml/min; L-NMMA  SNP:
.3  0.4 ml/100 ml/min; L-NMMA  SNP and ACH:
6.0  3.5 ml/100 ml/min, 384%). Under vitamin C,
esponse to ACH was significantly improved (from 3.3 
.4 ml/100 ml/min to 22.0  3.9 ml/100 ml/min, 567%;
 0.001 vs. ACH alone), and the inhibiting effect of
-NMMA on ACH was restored (baseline: 3.3  0.2 ml/
00 ml/min; vitamin C  L-NMMA: 2.0  0.3 ml/100
l/min; vitamin C  L-NMMA and SNP: 3.3  0.3
l/100 ml/min; vitamin C  L-NMMA, SNP, and ACH:
3.1  1.8 ml/100 ml/min, 296%).
In both normotensive subjects and hypertensive patients,
ontralateral FBF did not significantly change throughout
he study (data not shown).
ISCUSSION
he present results confirm that vasodilation to ACH and
DK, 2 specific endothelial agonists that stimulate G-
rotein–coupled receptors, but not to SNP, a dilator acting
irectly on smooth muscle cells, was blunted in hypertensive
atients as compared with control subjects, confirming the
resence of endothelial dysfunction in the peripheral circu-
ation of essential hypertensive patients (2–6). In addition,
hile in healthy subjects the vasodilator responses to ACH
nd BDK were blunted by L-NMMA, an inhibitor of NO
ynthase, indicating preserved NO availability, in essential
ypertensive patients vasodilation elicited by endothelial
gonists was found to be resistant to NO inhibition,
emonstrating the presence of impaired NO availability
5,6). Another relevant finding is that, in the same study
ubgroups, sulfaphenazole, a highly selective CYP 2C9
nhibitor, blunted the vasodilation elicited by ACH and
DK in hypertensive patients only, whereas it was ineffec-
ive in healthy subjects. Furthermore, the degree of inhibi-
ion exerted by the CYP 2C9 inhibitor was greater on
DK- as compared with ACH-induced vasodilation. Fi-
ally, the inhibitory effect of sulfaphenazole on endothelial
gonists was specific because the CYP 2C9 inhibitor did not
hange the response to SNP.
It is conceivable that, in these experimental conditions,
YP 2C9-induced vasodilation could be mediated by
DHF production, as indirectly supported by previous
vidence. Bradykinin-mediated, NO- and prostacyclin-
ndependent subcutaneous resistance artery vasodilation in
ealthy humans can be suppressed by high intravascular K
oncentrations, suggesting the involvement of an EDHF (18).
oreover, a CYP 2C isoform is involved in the ACH-
nduced EDHF generation in hamster gracilis muscle
11,19). In contrast, the present study does not allow
dentification of the chemical nature of the EDHF released
y CYP 2C9 stimulation. In this regard, in vitro evidence
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August 1, 2006:508–15 Hyperpolarization in Essential Hypertensionemonstrates that this enzyme can generate both 11,12- and
4,15-EET (7). Taken together, these results indicate that,
hile under healthy conditions, endothelium-dependent
asodilatation seems to be mainly dependent on NO pro-
uction; in essential hypertensive patients it is instead
elated to alternative pathways, including production of
YP 2C9-derived EDHF, which is activated to compensate
or the impaired NO availability. This possibility is further
igure 4. Forearm blood flow (FBF) percent increase above basal induced
igure 3. Forearm blood flow (FBF) percent increase above basal in
G-monomethyl-L-arginine (L-NMMA), sulfaphenazole, and L-NMMA
p  0.001; †p  0.01 (by analysis of variance for repeated measures andulfaphenazole, at baseline (control) and under vitamin C in essential hypertensiv
f variance for repeated measures and Scheffé’s test).einforced by the study evaluating the effect of sulfa-
henazole on vasodilation to ACH or BDK residual to
-NMMA and COX blockade in healthy subjects. In this
xperimental condition of decreased NO availability, sulfa-
henazole, while proving to be ineffective when tested in
ontrol conditions, produced a further decrease in the
esponse to both endothelial agonists. These results are in
erfect agreement with available evidence indicating that, in
etylcholine (upper panels) and bradykinin (lower panels) during saline or
d by acetylcholine (n  8) and bradykinin (n  8) during saline,
sulfaphenazole, in normotensive subjects. Data shown as mean  SEM.
ffé’s test).by acduce
pluse patients. Data shown as mean SEM. *p 0.05; †p 0.01 (by analysis
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Hyperpolarization in Essential Hypertension August 1, 2006:508–15he forearm microcirculation of healthy subjects, micon-
zole, a non-selective CYP inhibitor, is ineffective on
asodilation to BDK in baseline conditions (13). However,
fter NO synthase and COX inhibition by L-NMMA and
spirin, BDK-mediated vasodilation was suppressed by
iconazole, confirming that the EDHF contribution plays
primary role particularly in conditions characterized by
eranged NO availability (13). Therefore, these series of
bservations suggest that, in the peripheral human circula-
ion, a CYP 2C9-derived pathway may operate as a rapid
ompensatory mechanism for decreased NO activity. In this
cenario, we cannot exclude that BP levels might be influ-
nced by the magnitude of EDHF production. However,
he relatively small number of hypertensive patients re-
ruited in our study was characterized by a narrow range of
P values. Therefore, in such conditions, the expected
elationship between BP and response to sulfaphenazole
ould not have been put in evidence. This important issue
waits clarification in future studies.
The cross-talk between NO and CYP pathways is further
einforced by the demonstration that neither L-NMMA nor
ulphafenazole alone affect the increase in skeletal smooth
uscle blood flow induced by dynamic exercise (20). Only the
ombination of the 2 inhibitors is able to inhibit the flow
ncrease, thereby demonstrating that an interaction between
he 2 systems appears to exist, with EDHF-dependent vaso-
ilation taking over when NO availability is compromised.
The hypothetical cross-talk between NO and the EDHF
athway is not, however, in agreement with the possibility
hat exogenous NO derived from SNP utilized during the
NO clamp” could interfere with the effect of sulfa-
henazole on response to ACH. However, in adjunctive
xperiments, papaverine, a phosphodiesterase activity inhib-
tor, provided superimposable results. This apparent con-
rast might be explained by the low dose of the compound
tilized during the “NO clamp” technique. Indeed, such
oncentration, able to increase the FBF around 65%, cannot
elease enough exogenous NO to affect the EDHF pathway.
t is worth noting that the NO released by ACH accounts
or a greater amount of vasodilation (around 600%). How-
ver, because our experimental conditions do not allow us to
nvestigate these intracellular mechanisms, we recognize our
ypothesis as a speculative interpretation of our findings.
Further confirmation for this hypothesis comes from the
tudy with intrabrachial vitamin C. In agreement with
arlier evidence, the antioxidant increases the response to
oth ACH and BDK in essential hypertensive patients (5,6)
nd restores the sensitivity to L-NMMA, confirming that
xidative stress may be the main mechanism leading to
mpaired endothelium-dependent vasodilation by NO
reakdown in essential hypertension. However, the relevant
nding is that, under vitamin C administration, sulfa-
henazole proved no longer effective in blunting the re-
ponse to ACH and BDK. These results seem to indicate
hat, in essential hypertension, CYP 2C9-derived EDHF
cts as a partial compensatory mechanism to sustain endo- fhelial function when NO activity is impaired through the
resence of oxidative stress. Similar findings were obtained
n essential hypertensive patients, by preventing BDK-
nduced smooth muscle cell hyperpolarization with ouabain,
NaK/ATPase inhibitor (6). The present results extend
his previous information by identifying the nature of at
east 1 of the EDHFs involved.
The fact that the EDHF-mediated response becomes
vident only in the presence of impaired NO availability is
n line with experimental evidence indicating that physio-
ogical concentration of endothelial NO is sufficient to
ampen EDHF generation (21). In microsomes and endo-
helial cells, NO donors can inhibit CYP activity (7).
ifferent mechanisms can be proposed to account for the
O-induced inactivation of the CYP enzyme, including
elease of heme from CYP proteins, inhibition of CYP
rotein synthesis, or reaction between NO and superoxide
nions to form peroxynitrite, which, in turn, may affect CYP
xpression or function (7).
Another issue that can be addressed by the present results
s the finding that the degree of inhibition exerted by
ulphafenazole on BDK is greater than that exerted on
CH. This result is not easily interpretable. There is
vidence indicating that an increase in calcium influx,
nduced either as a result of endothelial surface B2 receptor
timulation by BDK or through muscarinic receptor activa-
ion by ACH, stimulates endothelial phospholipase A2 to
elease arachidonic acid, which can, in turn, be metabolized
y CYP enzymes (in addition to COX and lipoxygenase) (22).
hus, it is conceivable that these 2 agonists, which, however,
ct through different signal transduction pathways, might
xert a different degree of CYP 2C9 activation, despite a
imilar vasodilating effect. On the other hand, available
vidence in essential hypertension demonstrates that while
DK is sensitive to ouabain (6,23), ACH is resistant to the
aK/ATPase inhibitor in baseline conditions, although
certain effect can be unmasked after adequate stimulation
ith insulin (23). Therefore, it cannot be ruled out that
CH-induced NO-independent vasodilation could be
reatly dependent on pathways different from CYP 2C9-
ediated activation.
Finally, the present results do not support the possibility
hat, in essential hypertensive patients, CYP 2C9 might be
relevant source of oxidative stress, as demonstrated in
atients with coronary artery disease (15). This discrepancy
ould be explained by the different degree of cardiovascular
isk characterizing these 2 study populations. Because it is
emonstrated that the degree of endothelial dysfunction is
irectly related to total cardiovascular risk (24,25), it is con-
eivable that CYP 2C9 shifts from production of relaxing
DHF to a role as a major source of oxidative stress. Such
shift would represent 1 of the pathogenetic events associ-
ted with the increase in cardiovascular risk.
In conclusion, the results outlined in this paper provide
urther information concerning the mechanisms responsible
or impaired endothelium-dependent vasodilation in essen-
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August 1, 2006:508–15 Hyperpolarization in Essential Hypertensionial hypertension. Because it is becoming increasingly clear
hat endothelial dysfunction is an independent promoter of
therosclerosis and cardiovascular events (1), it is very likely
hat, in the near future, the determination of endothelium-
ependent relaxation could be utilized for quantification of
ardiovascular risk. In addition, restoration of endothelial
unction might become an adjunctive target of antihyper-
ensive therapy. Thus, identification of the pathways that
haracterize endothelial dysfunction can increase knowledge
n the pathophysiology of atherosclerotic disease and pro-
ide additional potential for the development of specific
trategies to improve endothelial dysfunction.
eprint requests and correspondence: Dr. Stefano Taddei,
epartment of Internal Medicine, University of Pisa, Via Roma,
7, 56100 Pisa, Italy. E-mail: s.taddei@med.unipi.it.
EFERENCES
1. Taddei S, Salvetti A. Endothelial dysfunction in essential hyperten-
sion: clinical implications. J Hypertens 2002;20:1671–4.
2. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal
endothelium dependent vascular relaxation in patients with essential
hypertension. N Engl J Med 1990;323:22–7.
3. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine
in primary and secondary forms of human hypertension. Hypertension
1993;21:929–33.
4. Panza JA, García CE, Kilcoyne CM, Quyyumi A, Cannon RO III.
Impaired endothelium-dependent vasodilation in patients with essen-
tial hypertension. Evidence that nitric oxide abnormality is not
localised to a single signal transduction pathway. Circulation 1995;91:
1732–8.
5. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C
improves endothelium-dependent vasodilatation by restoring nitric
oxide activity in essential hypertension. Circulation 1998;97:2222–9.
6. Taddei S, Virdis A, Taddei S, et al. Vasodilation to bradykinin is
mediated by an ouabain-sensitive pathway as a compensatory mecha-
nism for impaired NO availability in essential hypertensive patients.
Circulation 1999;100:1400–5.
7. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s).
Pharmacol Res 2004;49:525–33.
8. Komori K, Vanhoutte PM. Endothelium-derived hyperpolarizing
factor. Blood Vessels 1990;27:238–45.
9. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification
of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing
factors. Circ Res 1996;78:415–23.
0. Edwards G, Dora KA, Gardner MJ, Garland CJ, Weston AH. K is
an endothelium-derived hyperpolarizing factor in rat arteries. Nature1. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF
synthase in coronary arteries. Nature 1999;401:493–7.
2. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyper-
polarizing factor in human internal mammary artery is 11,12-
epoxyeicosatrienoic acid and causes relaxation by activating smooth
muscle BKCa channels. Circulation 2003;107:769–76.
3. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi
AA. Characterization of endothelium-derived hyperpolarizing factor
in the human forearm microcirculation. Am J Physiol Heart Circ
Physiol 2001;208:H2470–7.
4. Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived
hyperpolarizing factor synthase (cytochrome P450 2C9) is a function-
ally significant source of reactive oxygen species in coronary arteries.
Circ Res 2001;88:44–51.
5. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I.
Inhibition of cytochrome P450 2C9 improves endothelium-
dependent, nitric oxide-mediated vasodilatation in patients with
coronary artery disease. Circulation 2004;109:178–83.
6. Virdis A, Taddei S, Ghiadoni L, et al. Mechanisms responsible for
endothelial dysfunction induced by fasting hyperhomocyst(e)inemia in
normotensive subjects and essential hypertensive patients. J Am Coll
Cardiol 2001;38:1106–15.
7. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant
in human blood plasma. Proc Natl Acad Sci U S A 1989;86:6377–81.
8. Coats P, Johnston F, MacDonald J, McMurray JJV, Hillier C.
Endothelium-derived hyperpolarizing factor. Identification and mech-
anisms of action in human subcutaneous resistance arteries. Circula-
tion 2001;103:1702–8.
9. Bolz SB, Fisslthaler B, Pieperhoff S, et al. Antisense oligonucleotides
against cytochrome P450 2C8 attenuate EDHF-mediated Ca2
changes and dilation in isolated resistance arteries. FASEB J 2000;14:
255–60.
0. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, Hellsten Y.
Cytochrome P450 2C9 plays an important role in the regulation of
exercise-induced skeletal muscle blood flow and oxygen uptake in
humans. J Physiol 2003;546:307–14.
1. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric
oxide attenuates the release of endothelium-derived hyperpolarizing
factor. Circulation 1996;94:3341–7.
2. Feletou M, Vanhoutte PM. Activation of vascular smooth muscle K
channels by endothelium-derived factors. In: Archer SL, Rusch NJ,
editors. Potassium Channels in Cardiovascular Biology. New York,
NY: Kluwer Academic/Plenum, 2001:691–712.
3. Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A.
Effect of insulin on acetylcholine-induced vasodilation in normoten-
sive subjects and patients with essential hypertension. Circulation
1995;92:2911–8.
4. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response
to acetylcholine relates to risk factors for coronary artery disease.
Circulation 1990;81:491–7.
5. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and
heritability of flow-mediated dilation in the community: the Framing-1998;396:269–72. ham Heart study. Circulation 2004;109:613–9.
